- Poster presentation
- Open Access
Diagnostic value of 18F-FDG-PET and PET-CT in children with fever of unknown origin or unexplained signs of inflammation
© Däbritz et al; licensee BioMed Central Ltd. 2008
- Published: 15 September 2008
- Positron Emission Tomography
- Pediatric Patient
- Computer Tomography
- Diagnostic Procedure
- Pathological Finding
Fever of unknown origin (FUO) and unexplained signs of inflammation are challenging medical problems and predominantly caused by infections, malignancies and noninfectious inflammatory diseases. The aim of this study was to assess the diagnostic value of fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET) and of its combination with computer tomography technology (PET-CT) in the diagnostic work-up in pediatric patients.
47 FDG-PET and 23 PET-CT-scans of 63 patients (median age 7,2 years, 32 M, 31 F) were analyzed in this retrospective study. The diagnostic value of PET investigations in pediatric patients presenting with FUO (group 1, n = 41 scans) or unexplained signs of inflammation without fever (group 2, n = 29 scans) was analyzed.
Of the total number of FDG-PET/PET-CT scans 32/57% were clinically helpful or diagnostic, respectively. In 54% (n = 38) of all scans the PET either was negative or findings could neither be confirmed nor excluded by extensive further diagnostic procedures. In scans with pathological findings (n = 32) further investigations confirmed the PET results in 81% (n = 26) of the cases. The accuracy of combined scans in these patients was 93%. A diagnosis in pediatric patients with FUO could be established in 32%, in patients with other signs of inflammation in 52%.
This is the first study demonstrating that FDG-PET and PET-CT may be a valuable imaging technique in the evaluation of children with FUO and unexplained signs of inflammation. Pathological findings help directing the diagnostic work-up in these patients. Because of its better accuracy, PET-CT is superior to 18F-FDG-PET.
This article is published under license to BioMed Central Ltd.